[ Price : $8.95]
FDA extends until 2/4 a temporary postponement of certain inspection activities due to the spread of the omicron variant.[ Price : $8.95]
The latest FDA user fee performance report shows the agency met or exceeded many of its FY 2020 PDUFA and BsUFA goals in several d...[ Price : $8.95]
Under the cloud of an HHS inspector general probe of alleged FDA coziness in the controversial approval of Biogens Alzheimers ther...[ Price : $8.95]
FDA tells Revance Therapeutics that to address a recent BLA complete response letter on DaxibotulinumtoxinA for Injection will req...[ Price : $8.95]
FDA approves a higher-yield manufacturing process for Akari Therapeutics nomacopan for use in two Phase 3 trials.[ Price : $8.95]
FDA schedules a 2/10 Webinar on its draft guidance on digital health technologies for remote data acquisition.[ Price : $8.95]
FDA puts a partial clinical hold on multi-dose trials of Yumanity Therapeutics investigational Parkinsons disease drug.[ Price : $8.95]
FDA accepts for review a Regeneron Pharmaceuticals supplemental BLA for PD-1 inhibitor Libtayo (cemiplimab-rwlc) in combination wi...